KLF4 and Hirschsprung disease: Instead, IF patient-derived intestinal organoids were used to verify the effect of DA on KLF4 in vitro, since emerging evidence has recently demonstrated that the development of patient-derived organoids may potentially create a novel way of experimentally investigating gastrointestinal diseases, including Hirschsprung’s disease and short bowel syndrome [41].